Regeneron Pharmaceuticals, Inc. (REGN) Presents at Truist Securities BioPharma Symposium (Transcript)

26 mins read
59 views

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Truist Securities BioPharma Symposium November 8, 2023 3:20 PM ET

Company Participants

Dr. Len Schleifer – President and Chief Executive Officer

Ryan Crowe – Investor Relations

Conference Call Participants

Robyn Shelton – Truist Securities

Robyn Shelton

Good morning, everyone. What a delight to have Dr. Len Schleifer here today. I think I’ve known Len since I was a baby analyst. A really bad one, but much better now. And with them, we also have Ryan Crowe from Investor Relations as well. So thank you so much.

Before we begin, both of us have to disclosures. So here are mine, because this is being webcast. So don’t scream anything out, it’s going to be transcribed and live. This call is arranged by Truist Securities Research for institutional investors and issuer clients only as defined by FINRA. If you’re not an individual investor or issuer, please disconnect this time. For required disclosures, please see our website at truistsecurities.com or equity research library.

So with that, I’ll turn it over to you.

Ryan Crowe

Now it’s my turn. Thank you, Robyn, for hosting us here at Truist. Great to be here. I’d like to remind you that our remarks made today may include forward-looking statements about Regeneron. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements.

A description of material risks and uncertainties can be found in Regeneron’s SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Len, do you want us to have a couple of minutes to open, and then…

Robyn Shelton

You want to red disclosure lines?

Dr. Len Schleifer

No. My only disclosure would be

Read the full article here

Leave a Reply

Your email address will not be published.

Previous Story

Smerconish: Will Trump be indicted into office?

Next Story

US consumer sentiment drops again in November, inflation expectations rise

Latest from News